Neoplasia/BPH

	Association between estimated glucose disposal rate and benign prostatic hyperplasia: results from two nationally representative population-based studies. Aging Male Liang H, Chen H, Wei Y. PMID: 42640724 [PubMed - indexed for MEDLINE]
	LRRC8A as a candidate biomarker of cisplatin sensitivity in muscle-invasive bladder cancer: an exploratory immunohistochemical study. Int Urol Nephrol Rytz MA, Hussung S, Frehner L, Beyer J, Scheidewind L, Roth B, Widmer C, Baaral A, Francica P, Rubin MA, Rottenberg S, Rodriguez-Calero A, Akhoundova D. PMID: 42640415 [PubMed - as supplied by publisher]
	Neuroendocrine Neoplasms of the Urinary Bladder: Integrating Molecular Advances into a Refined Classification System. Endocr Pathol Lobo A, Cheng L. PMID: 42640400 [PubMed - indexed for MEDLINE]
	Clinical value of prostate-specific antigen halving time as a predictor of response to first-line systemic treatment for synchronous metastatic castration-sensitive prostate cancer. Int J Clin Oncol Kambe T, Sumiyoshi T, Fujiwara H, Fujimoto T, Takahashi T, Mizuno K, Kubota M, Yamasaki T, Yoshimura K, Tamaki M, Nagumo Y, Kawanishi H, Miyazaki Y, Oshiro H, Kurahashi R, Masuda N, Makino Y, Kobori G, Akamatsu S, Morita S, Kobayashi T, Goto T. PMID: 42640376 [PubMed - as supplied by publisher]
	Dynamic Predictions and Predictimands for Salvage Therapy in Recurrent Prostate Cancer Using Joint Models. Stat Med Owens L, Rizopoulos D, Fainberg J, Carlsson S, Liso N, McBride S, Laudone V, Etzioni R, Taylor JMG. PMID: 42639747 [PubMed - indexed for MEDLINE]
	Stage-Specific Temporal Trends in Treatment Patterns and Overall Survival in Prostate Cancer: A Multicentre Real-World Cohort Study From KAMU-ON. Int J Urol Iwamoto H, Izumi K, Machioka K, Toriumi R, Shima T, Nozaki M, Hori T, Inaba T, Nakagawa R, Kamijima T, Kadomoto S, Makino T, Naito R, Yaegashi H, Shigehara K, Nohara T, Miyagi T, Seto C, Kadono Y, Mizokami A. PMID: 42639687 [PubMed - indexed for MEDLINE]
	Hereditary Prostate Cancer Risk Management: An Evidence-Based Summary to Inform Nursing Practice. J Multidiscip Healthc Jiang M, Chen Q, Chen X, Fu X, Chung SK. PMID: 42639254 [PubMed]
	Regulatory T cells in the bladder cancer tumor microenvironment: mechanisms of immune suppression and therapeutic opportunities. Front Mol Biosci Fukiage Y, Okubo N, Taga M, Sato Y, Terada N. PMID: 42639050 [PubMed]
	Urinary protein semi-quantification in immunochemotherapy for bladder cancer: markers of clinical outcomes. Front Immunol Chen H, Lin Y, Xue Z, Qie Y, Wu Z, Liu K, Huang S, Jia K, Yang S, Zhang Z, Li P, Li X, Liu L, Shen C, Hu H. PMID: 42639047 [PubMed - indexed for MEDLINE]
	Beyond supplements and surrogates: an evidence-quality map informs a strategic rebalancing of dietary research in prostate cancer active surveillance. Front Nutr Li Y, Wang TQ, Zhu AY, Zhang YP, Fu Q. PMID: 42638961 [PubMed]
	A locally deployed large language model for pathology-informed and nurse-reviewed communication support in bladder cancer immunotherapy. Front Med (Lausanne) Diao S, Zhao J, Liu X. PMID: 42638714 [PubMed]
	Combination treatment with intravesical interferon-alpha gene therapy and an oral pan-ErbB receptor family blocker improves survival in mice with bladder cancer. Front Mol Biosci Sood A, Martini A, Genitiano P, Rauf M, Manyam G, Rudzinski JK, Tholomier C, Contieri R, Lee IL, Parker NR, Yla-Herttuala S, McConkey DJ, Dinney CPN, Mokkapati S. PMID: 42638663 [PubMed]
	Evaluation of AI-based segmentation and synthetic CT generation for MRI-only prostate radiotherapy planning. J Appl Clin Med Phys Östensson A, Jonsson J. PMID: 42638512 [PubMed - indexed for MEDLINE]
	A rule-based, feedback-driven framework for fully automated prostate VMAT planning. J Appl Clin Med Phys Sangster J, Taylor M, Jolly D, Gastaldo J, Lorenz F. PMID: 42638300 [PubMed - indexed for MEDLINE]
	Safety and Efficacy of RezÅ«m Water Vapor Energy Therapy for Benign Prostatic Hyperplasia With Continued Antithrombotic Therapy: A Comparative Study. Low Urin Tract Symptoms Fujisawa N, Washino S, Yasuda Y, Maiya S, Shinozaki T. PMID: 42638164 [PubMed - indexed for MEDLINE]
	Clinical impact of routine secondâ€‘opinion reading of [Â¹â¸F]FDGâ€‘PET/CT in newly diagnosed invasive bladder cancer: A multicentre study in a centralised referral network. Eur J Nucl Med Mol Imaging Lijnen RAG, Vierling ML, Ringia JB, Hendricksen K, KleinJan GH, Postema AW, Vogel WV, Boellaard TN, Braat AJAT, Heijmen L, van Rhijn BWG, Mertens LS. PMID: 42637974 [PubMed - as supplied by publisher]
	Comment on "Frailty burden and symptomatic BPH/LUTS in aging men: evidence from two nationally representative population-based studies". World J Urol Suman, Banu S, Kaur J. PMID: 42637883 [PubMed - in process]
	Metallic versus polymeric ureteric stents for chronic malignant ureteric obstruction: a systematic review and meta-analysis. World J Urol Lim QY, Kyaw L, Ong CSH, Law YXT, Tiong HY. PMID: 42637852 [PubMed - indexed for MEDLINE]
	Post-translational modifications in prostate cancer: coordinated oncogenic networks and clinical implications. Biochim Biophys Acta Rev Cancer Ren H, Li X, Jiang Z, Bai Y, Ai J. PMID: 42637058 [PubMed - as supplied by publisher]
	High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial. Lancet Oncol Hennequin C, Sargos P, Roca L, Silva M, Latorzeff I, Peiffert D, Cozzi S, Benyoucef A, Hasbini A, Supiot S, Ronchin P, Wachter T, Azria D, Magne N, Zibouche M, Vial N, Cormier L. PMID: 42636837 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 190744

Page 1 of 9538



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy